Amarin Corp Plc (AMRN)

[north40000]

And the analysts, in print or on television and other media, have been advising to buy biotechnology companies, inasmuch as those companies are turning a corner and will advance the rest of 2022 into 2023. Really?

Indices such as GNOM, LABU, XBI, IBB remain close to bottoms for the year. Managing a portfolio of biotechs remains unpredictable day to day, dependent on trial results, income, milestones and royalties like always. More later on this topic.